Latest Conference Articles

CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer

December 8th 2021, 10:52pm

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.

Premenopausal ER+ Breast Cancer Recurrence Reduced Significantly With Aromatase Inhibitors

December 8th 2021, 10:14pm

San Antonio Breast Cancer Symposium

Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.

Treatment Options for Patients With HER2+ Breast Cancer With Brain Metastases

December 8th 2021, 9:45pm

San Antonio Breast Cancer Symposium

Alexandra S. Zimmer, MD, discusses treatment options for patients with HER2-positive breast cancer who have developed brain metastasis.

Poor Accuracy Seen with Standard IHC in Identifying Low HER2 Expression in Breast Cancer

December 8th 2021, 6:44pm

Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.

Higher Oncotype DX Scores Tied to Persistent Use of Endocrine Treatment in Breast Cancer

December 8th 2021, 5:34pm

San Antonio Breast Cancer Symposium

Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.

Datopotamab Deruxtecan Demonstrates Highly Promising Efficacy in Advanced or Metastatic TNBC

December 7th 2021, 10:32pm

San Antonio Breast Cancer Symposium

Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.

Adjuvant Pembrolizumab Continues to Prolong EFS Benefit in TNBC

December 7th 2021, 10:18pm

San Antonio Breast Cancer Symposium

Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.

Palbociclib Added to ET Not Beneficial in Early HR+, HER2- Breast Cancer

December 7th 2021, 9:53pm

Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.

Pembrolizumab/Chemotherapy Achieves Statistically Significant and Clinically Meaningful Survival Benefit in Metastatic TNBC Subset

December 7th 2021, 9:41pm

San Antonio Breast Cancer Symposium

Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.

Outcomes in Early Hormone Receptor-Positive or- Negative Breast Cancer Not Improved with Metformin

December 7th 2021, 7:10pm

San Antonio Breast Cancer Symposium

Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.